Cytarabine (Cytarabine): Uses, Dosage, Side Effects, Interactions, Warning
AML Refractory to 1 Cycle of High-Dose Cytarabine-Based Induction Chemotherapy
Acute Leukemias
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial - The
Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports
Genetic factors influencing cytarabine therapy | Pharmacogenomics
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene: Molecular Therapy
Dexamethasone Sensitizes Acute Monocytic Leukemia Cells to Ara-C by Upregulating FKBP51 - Frontiers
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
Frontiers | Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Fernand Bteich on Twitter: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
Chemotherapy regimen. | Download Table
Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
352-Consolidation HiDAC (cytarabine) 1,3,5 | eviQ
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study | Leukemia
Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram
Cytarabine | C9H13N3O5 - PubChem
![PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/094147101525dbcb98a9d514f1a305a20a3a7f7c/3-Table1-1.png "PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar")
PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar
Improved chemotherapy modeling with RAG-based immune deficient mice | PLOS ONE
Adult myeloid leukaemias: current and future treatments - The Pharmaceutical Journal
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
